Larimar Therapeutics
Stock Forecast, Prediction & Price Target
Larimar Therapeutics (LRMR) stock Price Target by analysts
$17
Potential upside: 356.98%
Larimar Therapeutics price prediction
What is Larimar Therapeutics stock analysts` prediction?
Larimar Therapeutics stock forecast: Based on 3 Wall Street analysts` predicted price targets for Larimar Therapeutics in the last 3 months, the avarage price target is $17, with a high forecast of $NaN. The average price target represents a 356.98% change from the last price of $3.72.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Larimar Therapeutics stock Price Target by analysts
Full breakdown of analysts given Larimar Therapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Edward White H.C. Wainwright | 0% 0/1 | 9 months ago | $15 303.22% upside | $4.28 | StreetInsider | Previous targets (0) |
Samantha Semenkow Citigroup | 0% 0/1 | 11 months ago | $14 276.34% upside | $8.46 | StreetInsider | Previous targets (0) |
Laura Chico Wedbush | 0% 0/1 | 12 months ago | $22 491.39% upside | $6.29 | TheFly | Previous targets (0) |
Joori Park Leerink Partners | 0% 0/1 | over 1 year ago | $25 572.04% upside | $7.57 | TheFly | Previous targets (0) |
Unknown Citigroup | N/A | almost 3 years ago | $4 7.52% upside | $3.97 | Benzinga | N/A |
Larimar Therapeutics Financial Estimates
Larimar Therapeutics Revenue Estimates
Larimar Therapeutics EBITDA Estimates
Larimar Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $0 0% | $0 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $27.22M Low: $27.22M High: $27.22M avg. 0% | Avg: $99.74M Low: $99.74M High: $99.74M avg. 266.31% | Avg: $219.42M Low: $219.42M High: $219.42M avg. 119.98% |
Net Income
% change YoY
| $-50.31M N/A | $-34.18M 32.05% | $-36.94M -8.08% | Avg: $-137.89M Low: $-106.24M High: $-85.16M avg. -273.20% | Avg: $-169.09M Low: $-121.60M High: $-76.38M avg. -22.62% | Avg: $-95.70M Low: $-95.70M High: $-95.70M avg. 43.40% | Avg: $-66.72M Low: $-66.72M High: $-66.72M avg. 30.27% |
EBITDA
% change YoY
| $-50.46M N/A | $-36.52M 27.62% | $-41.44M -13.47% | Avg: $0 Low: $0 High: $0 avg. 100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
EPS
% change YoY
| -$2.93 N/A | -$1.33 54.60% | -$0.84 36.84% | Avg: -$2.15 Low: -$2.42 High: -$1.94 avg. -155.95% | Avg: -$2.39 Low: -$2.77 High: -$1.74 avg. -11.00% | Avg: -$2.18 Low: -$2.18 High: -$2.18 avg. 8.65% | Avg: -$1.52 Low: -$1.52 High: -$1.52 avg. 30.27% |
Operating Expenses
% change YoY
| $50.46M N/A | $36.52M -27.62% | $41.75M 14.32% | Avg: $0 Low: $0 High: $0 avg. -100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
FAQ
What is Larimar Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of -55.53% in 2025-2028.
We have gathered data from 3 analysts. Their low estimate is -106.24M, average is -137.89M and high is -85.16M.
What is Larimar Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 96.57% in 2025-2028.
We have gathered data from 3 analysts. Their low revenue estimate is N/A, average is N/A and high is N/A.
What is Larimar Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of -32.00% in 2025-2028.
We have gathered data from 3 analysts. Their low earnings per share estimate is -$2.42, average is -$2.15 and high is $-1.94.
What is the best performing analyst?
In the last twelve months 3 analysts have been covering Larimar Therapeutics stock. The most successful analyst is Edward White.